PBL Communications, Inc. (Ticker: PBLS) is a dynamic player in the telecommunications sector, focusing on providing innovative communication solutions and services to both residential and commercial clients. Leveraging advanced technologies, the company is committed to enhancing connectivity and delivering high-quality customer experiences. With a strategic emphasis on expansion and the adoption of cutting-edge infrastructure, PBLS is well-positioned for growth in an increasingly digital landscape. The company's dedication to operational excellence and market responsiveness further solidifies its potential as a compelling investment opportunity for institutional stakeholders.
| Revenue (TTM) | 0 |
| Gross Profit (TTM) | 0 |
| EBITDA | $-153.67M |
| Operating Margin | 0.00% |
| Return on Equity | 0.00% |
| Return on Assets | 0.00% |
| Revenue/Share (TTM) | $0.00 |
| Book Value | $-174.15 |
| Price-to-Book | — |
| Price-to-Sales (TTM) | — |
| EV/Revenue | - |
| EV/EBITDA | — |
| Quarterly Earnings Growth (YoY) | 0.00% |
| Quarterly Revenue Growth (YoY) | 0.00% |
| Shares Outstanding | $120.73M |
| Float | $2.49M |
| % Insiders | 3.78% |
| % Institutions | 54.11% |
Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades, downgrades and initiations, please see our analyst ratings page.
CAMBRIDGE, Mass., June 11, 2026 (GLOBE NEWSWIRE) -- Parabilis Medicines, Inc. (Nasdaq: PBLS) (“Parabilis”), a clinical-stage biopharmaceutical company built to develop transformative medicines addressing some of the most consequential, yet historically undruggable, protein targets driving human disease, today announced the closing of its upsized initial public offering of an aggregate 38,525,000 shares of its common stock, including the full exercise by the underwriters of their overallotment option to purchase 5,025,000 additional shares, at an initial public offering price of $20.00 per share. All of the shares of common stock were offered by Parabilis. Parabilis' common stock began trading on the Nasdaq Global Select Market on June 10, 2026 under the ticker symbol “PBLS”.
CAMBRIDGE, Mass., June 09, 2026 (GLOBE NEWSWIRE) -- Parabilis Medicines, Inc. (Nasdaq: PBLS) (“Parabilis”), a clinical-stage biopharmaceutical company built to develop transformative medicines addressing some of the most consequential, yet historically undruggable, protein targets driving human disease, today announced the pricing of its upsized initial public offering of 33,500,000 shares of its common stock at a price to the public of $20.00 per share. In addition, Parabilis has granted the underwriters a 30-day option to buy an additional 5,025,000 shares of its common stock at the initial public offering price, less underwriting discounts and commissions.
Biopharmaceutical company Parabilis Medicines said on Tuesday it was aiming to raise as much as $633.3 million in its upsized initial public offering in the U.S.
